The 62nd Annual Meeting of the European Association for the Study of Diabetes opens today in Milan, and data scheduled for release this week could shape which diabetes and weight-loss drugs American patients hear about next. The meeting runs through Oct. 2 and is expected to draw thousands of researchers and clinicians.
The most closely watched presentations come from Eli Lilly and Novo Nordisk, the makers of Mounjaro, Zepbound, Ozempic, and Wegovy. Most of the new numbers released so far are company topline results or conference abstracts, not peer-reviewed papers, and none of the new findings change current prescribing guidance.
